CA2731490A1 - Early detection of lysosomal storage disorders - Google Patents
Early detection of lysosomal storage disorders Download PDFInfo
- Publication number
- CA2731490A1 CA2731490A1 CA2731490A CA2731490A CA2731490A1 CA 2731490 A1 CA2731490 A1 CA 2731490A1 CA 2731490 A CA2731490 A CA 2731490A CA 2731490 A CA2731490 A CA 2731490A CA 2731490 A1 CA2731490 A1 CA 2731490A1
- Authority
- CA
- Canada
- Prior art keywords
- lsd
- lamp
- mps
- antibody
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000015439 Lysosomal storage disease Diseases 0.000 title claims abstract description 153
- 238000001514 detection method Methods 0.000 title abstract description 25
- 238000000034 method Methods 0.000 claims description 65
- 239000003550 marker Substances 0.000 claims description 49
- 208000002678 Mucopolysaccharidoses Diseases 0.000 claims description 43
- 206010028093 mucopolysaccharidosis Diseases 0.000 claims description 43
- 210000002950 fibroblast Anatomy 0.000 claims description 36
- 210000002381 plasma Anatomy 0.000 claims description 34
- 210000004369 blood Anatomy 0.000 claims description 27
- 239000008280 blood Substances 0.000 claims description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 27
- 239000000523 sample Substances 0.000 claims description 26
- 208000022018 mucopolysaccharidosis type 2 Diseases 0.000 claims description 23
- 238000011282 treatment Methods 0.000 claims description 19
- 239000000427 antigen Substances 0.000 claims description 17
- 108091007433 antigens Proteins 0.000 claims description 17
- 102000036639 antigens Human genes 0.000 claims description 17
- 239000012472 biological sample Substances 0.000 claims description 16
- 239000000284 extract Substances 0.000 claims description 12
- 238000012544 monitoring process Methods 0.000 claims description 11
- 206010072927 Mucolipidosis type I Diseases 0.000 claims description 10
- 208000013608 Salla disease Diseases 0.000 claims description 10
- 208000000828 Sialic Acid Storage Disease Diseases 0.000 claims description 10
- 208000015872 Gaucher disease Diseases 0.000 claims description 9
- 108010064171 Lysosome-Associated Membrane Glycoproteins Proteins 0.000 claims description 9
- 102000014944 Lysosome-Associated Membrane Glycoproteins Human genes 0.000 claims description 9
- 230000002452 interceptive effect Effects 0.000 claims description 9
- 210000002966 serum Anatomy 0.000 claims description 9
- 208000032007 Glycogen storage disease due to acid maltase deficiency Diseases 0.000 claims description 8
- 206010053185 Glycogen storage disease type II Diseases 0.000 claims description 8
- 102100033448 Lysosomal alpha-glucosidase Human genes 0.000 claims description 8
- 238000004113 cell culture Methods 0.000 claims description 8
- 201000004502 glycogen storage disease II Diseases 0.000 claims description 8
- 208000005340 mucopolysaccharidosis III Diseases 0.000 claims description 8
- 210000002700 urine Anatomy 0.000 claims description 8
- 230000007812 deficiency Effects 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- 208000017462 Galactosialidosis Diseases 0.000 claims description 5
- 230000001413 cellular effect Effects 0.000 claims description 5
- 208000027933 Mannosidase Deficiency disease Diseases 0.000 claims description 4
- 208000022292 Tay-Sachs disease Diseases 0.000 claims description 4
- 208000009796 Gangliosidoses Diseases 0.000 claims description 3
- 206010028095 Mucopolysaccharidosis IV Diseases 0.000 claims description 3
- 201000006440 gangliosidosis Diseases 0.000 claims description 3
- 208000012253 mucopolysaccharidosis IVA Diseases 0.000 claims description 3
- 102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 claims description 2
- 208000021811 Sandhoff disease Diseases 0.000 claims description 2
- 208000026589 Wolman disease Diseases 0.000 claims description 2
- 208000027333 mucopolysaccharidosis type IIID Diseases 0.000 claims description 2
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 claims 3
- 101710116782 Lysosome-associated membrane glycoprotein 1 Proteins 0.000 claims 3
- 241001465754 Metazoa Species 0.000 abstract description 17
- 102000013563 Acid Phosphatase Human genes 0.000 abstract description 15
- 108010051457 Acid Phosphatase Proteins 0.000 abstract description 15
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 abstract description 13
- 101150048357 Lamp1 gene Proteins 0.000 abstract description 11
- 101150117895 LAMP2 gene Proteins 0.000 abstract description 4
- 239000000032 diagnostic agent Substances 0.000 abstract description 4
- 229940039227 diagnostic agent Drugs 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 138
- 102000004190 Enzymes Human genes 0.000 description 54
- 108090000790 Enzymes Proteins 0.000 description 54
- 229940088598 enzyme Drugs 0.000 description 54
- 229930006000 Sucrose Natural products 0.000 description 39
- 239000005720 sucrose Substances 0.000 description 39
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 38
- 108090000623 proteins and genes Proteins 0.000 description 35
- 238000003556 assay Methods 0.000 description 34
- 230000002132 lysosomal effect Effects 0.000 description 33
- 102000004169 proteins and genes Human genes 0.000 description 33
- 238000012937 correction Methods 0.000 description 27
- 238000003860 storage Methods 0.000 description 26
- 208000035475 disorder Diseases 0.000 description 19
- 230000000694 effects Effects 0.000 description 19
- 238000010166 immunofluorescence Methods 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- 238000003018 immunoassay Methods 0.000 description 17
- 238000001493 electron microscopy Methods 0.000 description 16
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 14
- 239000001573 invertase Substances 0.000 description 14
- 235000011073 invertase Nutrition 0.000 description 14
- 210000001626 skin fibroblast Anatomy 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 12
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 11
- 210000003712 lysosome Anatomy 0.000 description 11
- 230000001868 lysosomic effect Effects 0.000 description 11
- 239000002953 phosphate buffered saline Substances 0.000 description 11
- 210000003934 vacuole Anatomy 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 238000012216 screening Methods 0.000 description 10
- 108010009254 Lysosomal-Associated Membrane Protein 1 Proteins 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- 210000004379 membrane Anatomy 0.000 description 9
- 239000012528 membrane Substances 0.000 description 9
- 229920001184 polypeptide Polymers 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 230000000875 corresponding effect Effects 0.000 description 8
- 210000004408 hybridoma Anatomy 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- 230000008859 change Effects 0.000 description 7
- 238000012512 characterization method Methods 0.000 description 7
- 238000003745 diagnosis Methods 0.000 description 7
- 238000002372 labelling Methods 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 229920002971 Heparan sulfate Polymers 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000002820 assay format Methods 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 238000002641 enzyme replacement therapy Methods 0.000 description 6
- 239000007850 fluorescent dye Substances 0.000 description 6
- 230000007170 pathology Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- -1 Limp-II Proteins 0.000 description 5
- 239000012131 assay buffer Substances 0.000 description 5
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 230000008436 biogenesis Effects 0.000 description 5
- 238000000635 electron micrograph Methods 0.000 description 5
- 238000001000 micrograph Methods 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 210000002826 placenta Anatomy 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 102100035028 Alpha-L-iduronidase Human genes 0.000 description 4
- 101001019502 Homo sapiens Alpha-L-iduronidase Proteins 0.000 description 4
- 201000011442 Metachromatic leukodystrophy Diseases 0.000 description 4
- 208000028781 Mucopolysaccharidosis type 1 Diseases 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000001952 enzyme assay Methods 0.000 description 4
- 238000001215 fluorescent labelling Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000037311 normal skin Effects 0.000 description 4
- 238000002731 protein assay Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- FPJHWYCPAOPVIV-VOZMEZHOSA-N (2R,3S,4R,5R,6R)-6-[(2R,3R,4R,5R,6R)-5-acetamido-2-(hydroxymethyl)-6-methoxy-3-sulfooxyoxan-4-yl]oxy-4,5-dihydroxy-3-methoxyoxane-2-carboxylic acid Chemical compound CO[C@@H]1O[C@H](CO)[C@H](OS(O)(=O)=O)[C@H](O[C@@H]2O[C@H]([C@@H](OC)[C@H](O)[C@H]2O)C(O)=O)[C@H]1NC(C)=O FPJHWYCPAOPVIV-VOZMEZHOSA-N 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
- 101710088194 Dehydrogenase Proteins 0.000 description 3
- 229920000045 Dermatan sulfate Polymers 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 102000030902 Galactosyltransferase Human genes 0.000 description 3
- 108060003306 Galactosyltransferase Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 208000014060 Niemann-Pick disease Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 3
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 238000010322 bone marrow transplantation Methods 0.000 description 3
- 239000001110 calcium chloride Substances 0.000 description 3
- 229910001628 calcium chloride Inorganic materials 0.000 description 3
- 235000011148 calcium chloride Nutrition 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 201000008049 fucosidosis Diseases 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 229910052747 lanthanoid Inorganic materials 0.000 description 3
- 229960003151 mercaptamine Drugs 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000011537 solubilization buffer Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 235000021538 Chard Nutrition 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108010062580 Concanavalin A Proteins 0.000 description 2
- 206010011777 Cystinosis Diseases 0.000 description 2
- 229910052693 Europium Inorganic materials 0.000 description 2
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- 229920000288 Keratan sulfate Polymers 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 101710202061 N-acetyltransferase Proteins 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 208000025804 Sanfilippo syndrome type D Diseases 0.000 description 2
- 229940100228 acetyl coenzyme a Drugs 0.000 description 2
- 238000001261 affinity purification Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000007978 cacodylate buffer Substances 0.000 description 2
- 238000013216 cat model Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 238000011833 dog model Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 208000016361 genetic disease Diseases 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000003125 immunofluorescent labeling Methods 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 108010045758 lysosomal proteins Proteins 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 208000036725 mucopolysaccharidosis type 3D Diseases 0.000 description 2
- 208000025919 mucopolysaccharidosis type 7 Diseases 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 230000008723 osmotic stress Effects 0.000 description 2
- 230000005298 paramagnetic effect Effects 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 210000005152 placental membrane Anatomy 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000001044 red dye Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- BCHIXGBGRHLSBE-UHFFFAOYSA-N (4-methyl-2-oxochromen-7-yl) dihydrogen phosphate Chemical compound C1=C(OP(O)(O)=O)C=CC2=C1OC(=O)C=C2C BCHIXGBGRHLSBE-UHFFFAOYSA-N 0.000 description 1
- BHNQPLPANNDEGL-UHFFFAOYSA-N 2-(4-octylphenoxy)ethanol Chemical compound CCCCCCCCC1=CC=C(OCCO)C=C1 BHNQPLPANNDEGL-UHFFFAOYSA-N 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
- PSGQCCSGKGJLRL-UHFFFAOYSA-N 4-methyl-2h-chromen-2-one Chemical group C1=CC=CC2=C1OC(=O)C=C2C PSGQCCSGKGJLRL-UHFFFAOYSA-N 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000238097 Callinectes sapidus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 206010053684 Cerebrohepatorenal syndrome Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 208000006069 Corneal Opacity Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 208000024720 Fabry Disease Diseases 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 108010000540 Hexosaminidases Proteins 0.000 description 1
- 102000002268 Hexosaminidases Human genes 0.000 description 1
- 101000923070 Homo sapiens Arylsulfatase B Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 102000019218 Mannose-6-phosphate receptors Human genes 0.000 description 1
- 108050006616 Mannose-6-phosphate receptors Proteins 0.000 description 1
- 108010054377 Mannosidases Proteins 0.000 description 1
- 102000001696 Mannosidases Human genes 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 208000008955 Mucolipidoses Diseases 0.000 description 1
- 206010072928 Mucolipidosis type II Diseases 0.000 description 1
- 206010056886 Mucopolysaccharidosis I Diseases 0.000 description 1
- 208000025915 Mucopolysaccharidosis type 6 Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 208000008457 Neurologic Manifestations Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 201000011252 Phenylketonuria Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 208000036623 Severe mental retardation Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 108010061312 Sphingomyelin Phosphodiesterase Proteins 0.000 description 1
- 241000269319 Squalius cephalus Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- 201000004525 Zellweger Syndrome Diseases 0.000 description 1
- 208000036813 Zellweger spectrum disease Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 102000010126 acid sphingomyelin phosphodiesterase activity proteins Human genes 0.000 description 1
- 239000007801 affinity label Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 238000013096 assay test Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- HOQPTLCRWVZIQZ-UHFFFAOYSA-H bis[[2-(5-hydroxy-4,7-dioxo-1,3,2$l^{2}-dioxaplumbepan-5-yl)acetyl]oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HOQPTLCRWVZIQZ-UHFFFAOYSA-H 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 239000012973 diazabicyclooctane Substances 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 1
- UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000003822 epoxy resin Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000003013 erythroid precursor cell Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 238000007421 fluorometric assay Methods 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 229930192878 garvin Natural products 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000003017 in situ immunoassay Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 210000005061 intracellular organelle Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 150000002602 lanthanoids Chemical class 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 208000020460 mucolipidosis II alpha/beta Diseases 0.000 description 1
- 208000000690 mucopolysaccharidosis VI Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 208000011392 nephropathic cystinosis Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 239000012285 osmium tetroxide Substances 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000003793 prenatal diagnosis Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 231100001055 skeletal defect Toxicity 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 210000001768 subcellular fraction Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000003445 sucroses Chemical class 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000001685 time-resolved fluorescence spectroscopy Methods 0.000 description 1
- 229950003937 tolonium Drugs 0.000 description 1
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 1
- ZMBHCYHQLYEYDV-UHFFFAOYSA-N trioctylphosphine oxide Chemical compound CCCCCCCCP(=O)(CCCCCCCC)CCCCCCCC ZMBHCYHQLYEYDV-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPN9917 | 1996-05-17 | ||
| AUPN9917A AUPN991796A0 (en) | 1996-05-17 | 1996-05-17 | Early detection of lysosomal storage disorders |
| CA2253875A CA2253875C (en) | 1996-05-17 | 1997-05-16 | Early detection of lysosomal storage disorders |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2253875A Division CA2253875C (en) | 1996-05-17 | 1997-05-16 | Early detection of lysosomal storage disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2731490A1 true CA2731490A1 (en) | 1997-11-27 |
Family
ID=3794228
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2731490A Abandoned CA2731490A1 (en) | 1996-05-17 | 1997-05-16 | Early detection of lysosomal storage disorders |
| CA2253875A Expired - Fee Related CA2253875C (en) | 1996-05-17 | 1997-05-16 | Early detection of lysosomal storage disorders |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2253875A Expired - Fee Related CA2253875C (en) | 1996-05-17 | 1997-05-16 | Early detection of lysosomal storage disorders |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US6759189B1 (https=) |
| EP (1) | EP1021725B1 (https=) |
| JP (3) | JP3837711B2 (https=) |
| AT (1) | ATE426169T1 (https=) |
| AU (1) | AUPN991796A0 (https=) |
| CA (2) | CA2731490A1 (https=) |
| DE (1) | DE69739317D1 (https=) |
| IL (1) | IL127033A (https=) |
| NZ (1) | NZ332641A (https=) |
| WO (1) | WO1997044668A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1181550A4 (en) * | 1999-04-30 | 2005-03-02 | Nathan S Kline Inst For Psychi | METHODS OF IDENTIFYING COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE |
| US7090987B1 (en) | 1999-04-30 | 2006-08-15 | Nixon Ralph A | Methods for the identification of compounds for the treatment of neuronal atrophy-associated dementia |
| ATE550664T1 (de) | 2003-03-31 | 2012-04-15 | Womens & Childrens Hospital | Multiplex-screening auf lysosomale speicherkrankheiten (lsds) |
| US7615224B2 (en) | 2004-12-02 | 2009-11-10 | Women's And Children's Hospital | Multiplex-bead complex for determination of lysosomal storage disorders |
| ES2301280A1 (es) * | 2005-05-16 | 2008-06-16 | Fina Biotech S.L.U. | Metodo para diagnosticar la enfermedad de alzheimer. |
| WO2007136782A2 (en) * | 2006-05-19 | 2007-11-29 | Historx, Inc. | Kits and methods for evaluating misfolded proteins |
| WO2008070892A1 (en) * | 2006-12-13 | 2008-06-19 | Tgr Biosciences Pty Ltd | Promoting production of extracellular matrix by fibroblast cells and/or promoting migration of fibroblast cells |
| AU2009223092A1 (en) * | 2008-03-12 | 2009-09-17 | Amicus Therapeutics, Inc | Treatment of Pompe disease with specific pharmacological chaperones and monitoring treatment using surrogate markers |
| US8497122B2 (en) * | 2008-04-11 | 2013-07-30 | Washington University | Biomarkers for Niemann-pick C disease and related disorders |
| GB201114909D0 (en) * | 2011-08-30 | 2011-10-12 | San Raffaele Centro Fond | Biomarkers for lysosomal storage disorders |
| US8293487B1 (en) * | 2012-01-06 | 2012-10-23 | Jiandi Zhang | Zestern, a simple, fast, specific and quantifiable improvement of immunodetection process |
| WO2014153083A1 (en) | 2013-03-14 | 2014-09-25 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Compositions and methods for predicting age of onset of a lysosomal storage disease or a disease associated with a lysosomal defect |
| US12020820B1 (en) | 2017-03-03 | 2024-06-25 | Cerner Innovation, Inc. | Predicting sphingolipidoses (fabry's disease) and decision support |
| US11335461B1 (en) | 2017-03-06 | 2022-05-17 | Cerner Innovation, Inc. | Predicting glycogen storage diseases (Pompe disease) and decision support |
| US11923048B1 (en) | 2017-10-03 | 2024-03-05 | Cerner Innovation, Inc. | Determining mucopolysaccharidoses and decision support tool |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4859581A (en) * | 1986-03-10 | 1989-08-22 | Board Of Regents, The University Of Texas System | Endoglycosidase assay |
| AU2990692A (en) | 1991-12-06 | 1993-06-10 | Commonwealth Scientific And Industrial Research Organisation | Diagnostic method for pompe's disease |
| WO1994010340A1 (en) * | 1992-10-30 | 1994-05-11 | Mt. Sinai Hospital Corporation | Method for measuring glycosyltransferase activity |
-
1996
- 1996-05-17 AU AUPN9917A patent/AUPN991796A0/en not_active Abandoned
-
1997
- 1997-05-16 JP JP54126497A patent/JP3837711B2/ja not_active Expired - Fee Related
- 1997-05-16 WO PCT/AU1997/000304 patent/WO1997044668A1/en not_active Ceased
- 1997-05-16 US US09/180,657 patent/US6759189B1/en not_active Expired - Fee Related
- 1997-05-16 NZ NZ332641A patent/NZ332641A/xx not_active IP Right Cessation
- 1997-05-16 CA CA2731490A patent/CA2731490A1/en not_active Abandoned
- 1997-05-16 CA CA2253875A patent/CA2253875C/en not_active Expired - Fee Related
- 1997-05-16 IL IL12703397A patent/IL127033A/xx not_active IP Right Cessation
- 1997-05-16 DE DE69739317T patent/DE69739317D1/de not_active Expired - Lifetime
- 1997-05-16 AT AT97920460T patent/ATE426169T1/de not_active IP Right Cessation
- 1997-05-16 EP EP97920460A patent/EP1021725B1/en not_active Expired - Lifetime
-
2004
- 2004-01-13 US US10/756,011 patent/US20040191847A1/en not_active Abandoned
-
2005
- 2005-09-28 JP JP2005283143A patent/JP4260152B2/ja not_active Expired - Fee Related
-
2008
- 2008-08-19 JP JP2008211239A patent/JP2008289501A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| NZ332641A (en) | 2000-05-26 |
| US20040191847A1 (en) | 2004-09-30 |
| DE69739317D1 (de) | 2009-04-30 |
| JP3837711B2 (ja) | 2006-10-25 |
| ATE426169T1 (de) | 2009-04-15 |
| EP1021725B1 (en) | 2009-03-18 |
| IL127033A0 (en) | 1999-09-22 |
| AUPN991796A0 (en) | 1996-06-13 |
| JP4260152B2 (ja) | 2009-04-30 |
| WO1997044668A1 (en) | 1997-11-27 |
| JP2008289501A (ja) | 2008-12-04 |
| CA2253875A1 (en) | 1997-11-27 |
| JP2006061161A (ja) | 2006-03-09 |
| EP1021725A1 (en) | 2000-07-26 |
| IL127033A (en) | 2000-12-06 |
| JP2001519894A (ja) | 2001-10-23 |
| US6759189B1 (en) | 2004-07-06 |
| CA2253875C (en) | 2011-02-22 |
| EP1021725A4 (en) | 2002-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2253875C (en) | Early detection of lysosomal storage disorders | |
| JP3544544B2 (ja) | 診断マーカーとしてのヒト好中球リポカリン（ｈｎｌ）の使用および抗−ｈｎｌ−抗体調製物 | |
| JP5679818B2 (ja) | 早期妊娠診断のための組成物および方法 | |
| JP5301719B2 (ja) | リソソーム病の検出方法 | |
| US20050196818A1 (en) | Antibodies to alpha-synuclein | |
| Igarashi et al. | Acid phosphatases as markers of bone metabolism | |
| US6096555A (en) | Process for characterizing the glycosylation of glyco-proteins and for the in vitro determination of the bio-availability of glyco-proteins | |
| CA2390778C (en) | Organ transplant rejection and associated conditions | |
| JP2010139511A (ja) | サポシンおよび他のマーカーを用いるリソソーム貯蔵障害の診断 | |
| AU714818B2 (en) | Early detection of lysosomal storage disorders | |
| US20200116735A1 (en) | Non-Glycosylated suPar Biomarkers and Uses Thereof | |
| JP5090332B2 (ja) | 炎症及び感染症のためのバイオマーカーとしての短鎖ｓｒｌアルコールデヒドロゲナーゼ（ｄｈｒｓ４）の測定 | |
| US8105788B2 (en) | Mucopolysaccharidosis (MPS) diagnostic methods, systems, kits and assays associated therewith | |
| US7378231B1 (en) | Diagnosis of lysosomal storage disorders using saposins and other markers | |
| US7361481B2 (en) | Diagnosis of lysosomal storage disorders using saposins and other markers | |
| JP4703008B2 (ja) | 被験体におけるリソソーム貯蔵障害の診断またはモニターのために少なくとも１つのサポシンのレベルを使用する方法 | |
| US9746458B2 (en) | Dynactin subunit p62 biomarker for neurological conditions | |
| CN115639371A (zh) | 一种反映脂联素质量浓度的试剂盒及其使用方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |
Effective date: 20130218 |